p53 protein expression in chronic lymphocytic leukemia

References

• Seiler T, Döhner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Semin Oncol 2006;33:186–194.
   PubMed Web of Science ®Google Scholar
• Binet JL, Caligaris-Cappio F, Catovsky D, . Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859–861.
   PubMed Web of Science ®Google Scholar
• Gunnarsson R, Staaf J, Jansson M, . Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia—a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008;47:697–711.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Fischer K, . Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Leukemia 1997;11(Suppl. 2):S19–S24.
   Google Scholar
• Calin GA, Dumitru CD, Shimizu M, . Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99: 15524–15529.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Döhner H. Genotypic prognostic markers. Curr Top Microbiol Immunol 2005;294:147–164.
   PubMed Web of Science ®Google Scholar
• Fabbri G, Rasi S, Rossi D, . Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389–1401.
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101–105.
   PubMed Web of Science ®Google Scholar
• Malcikova J, Smardova J, Rocnova L, . Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009;114:5307–5314.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Dewald GW, Brockman SR, Paternoster SF, . Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003;121:287–295.
   PubMed Web of Science ®Google Scholar
• Thornton PD, Gruszka-Westwood AM, Hamoudi RA, . Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 2004;5:47–54.
   PubMedGoogle Scholar
• Van Den NE, Robin V, Francart J, . Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia 2007;21:1715–1722.
   PubMed Web of Science ®Google Scholar
• Saddler C, Ouillette P, Kujawski L, . Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008;111:1584–1593.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, . TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473–4479.
   PubMed Web of Science ®Google Scholar
• Zenz T, Benner A, Dohner H, . Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008;7:3810–3814.
   PubMed Web of Science ®Google Scholar
• Chang H, Jiang AM, Qi CX. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia. Am J Clin Pathol 2010;133:70–74.
   PubMed Web of Science ®Google Scholar
• Marinelli M, Raponi S, Del Giudice I, . Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia? Am J Clin Pathol 2011;135:173–174.
   PubMed Web of Science ®Google Scholar
• Olivares-Illana V, Fahraeus R. p53 isoforms gain functions. Oncogene 2010;29:5113–5119.
   PubMed Web of Science ®Google Scholar
• Bourdon JC. p53 and its isoforms in cancer. Br J Cancer 2007; 97:277–282.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Nückel H, Frey UH, Bau M, . Association of a novel regulatory polymorphism (-938C > A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007;109:290–297.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Sellmann L, Scholtysik R, Kreuz M, . Gene dosage effects in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010;203: 149–160.
   PubMed Web of Science ®Google Scholar
• Feuerborn A, Moritz C, Von BF, . Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma. Leuk Lymphoma 2006;47:1932–1940.
   PubMed Web of Science ®Google Scholar
• Nückel H, Hüttmann A, Klein-Hitpass L, . Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:1053–1061.
   PubMed Web of Science ®Google Scholar
• Bourdon JC, Fernandes K, Murray-Zmijewski F, . p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19: 2122–2137.
   PubMed Web of Science ®Google Scholar
• Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15–16.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Lichter P, Döhner H. Genetic features of B-cell chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4: 48–72.
   PubMedGoogle Scholar
• Zenz T, Mertens D, Küppers R, . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10:37–50.
   PubMed Web of Science ®Google Scholar
• Graupner V, Schulze-Osthoff K, Essmann F, . Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle 2009;8:1238–1248.
   PubMed Web of Science ®Google Scholar
• Anensen N, Oyan AM, Bourdon JC, . A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 2006;12:3985–3992.
   PubMed Web of Science ®Google Scholar
• Boldrup L, Bourdon JC, Coates PJ, . Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 2007;43:617–623.
   PubMed Web of Science ®Google Scholar
• Fujita K, Mondal AM, Horikawa I, . p53 isoforms delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009;11:1135–1142.
   PubMed Web of Science ®Google Scholar
• Christodoulopoulos G, Fotouhi N, Krajewski S, . Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53. Cancer Lett 1997;121:59–67.
   PubMed Web of Science ®Google Scholar
• Fitzgibbon J, Smith LL, Raghavan M, . Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005;65:9152–9154.
   PubMed Web of Science ®Google Scholar
• Raghavan M, Lillington DM, Skoulakis S, . Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005;65:375–378.
   PubMed Web of Science ®Google Scholar
• Teh MT, Blaydon D, Chaplin T, . Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 2005;65: 8597–8603.
   PubMed Web of Science ®Google Scholar